BriaCell BCTX 深 沪
等待开盘 05-19 09:30:00 美东时间
3.35
+0.330
+10.93%
华盛通- 最 高3.40
- 今 开3.11
- 成交量 36.67万股
- 最 低 3.11
- 昨 收 3.02
- 总市值 2428.91万
- 52周最高 36.90
- 市盈率 静 --
- 换手率 5.06%
- 52周最低 2.98
- 委 比 -3.01%
- 总股本 725.05万
- 历史最高 1860.5799
- 量 比 0.83
- 振 幅 9.60%
- 历史最低 2.98
- 每 手 1
- 风险率 9.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BriaCell Therapeutics Completes Manufacturing Clinical Supplies Of Bria-PROS+ For Prostate Cancer
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it has completed
05-14 19:39
BriaCell Therapeutics Receives FDA Clearance To Initiate Clinical Evaluation Of Bria-BRES+, Its Next Generation Cell-Based Immunotherapy For Metastatic Breast Cancer
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation personalized immunotherapy
05-06 19:37
BriaCell Therapeutics Presents One Poster Featuring Data From Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor, And Two Posters Highlighting Further Analyses Of Phase 2 Data At 2026 AACR Annual Meeting
Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of potential
04-20 19:34
BriaCell Therapeutics Reports Rising Losses and Funding Pressure
An announcement from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. On ...
04-01 07:35
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
BriaCell Therapeutics Corp. and its subsidiary BriaPro Therapeutics Corp. have completed an asset purchase transaction under which BriaPro acquired the exclusive license for sCD80, a promising immunotherapy for cancer treatment. BriaPro is now responsible for developing and commercializing sCD80, with BriaCell retaining a significant ownership stake of approximately 78%. As part of the deal, BriaCell provided up to $3 million in funding to suppor...
03-31 20:05
BriaCell Therapeutics To Present Four Posters At 2026 American Association For Cancer Research Annual Meeting
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it
03-18 19:35
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
BriaCell Therapeutics Corp. will present four posters at the 2026 AACR Annual Meeting in San Diego, showcasing positive clinical and preclinical data for its immunotherapies. The posters include results from a pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor, analyses of Phase 2 data, and preclinical findings on Bria-OTS+, a next-generation personalized immunotherapy targeting breast, prostate, lung, and melanoma cancers. The...
03-18 11:30
BriaCell Secures Prime Spotlight at Major 2026 Cancer Conference to Reveal 'Next-Gen' Personalized Immunotherapy Progress
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that four
03-10 19:36
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
BriaCell Therapeutics Corp. announced that four abstracts related to its immunotherapy platform, including its Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor, have been accepted for poster presentation at the 2026 AACR Annual Meeting in San Diego. The posters will highlight research supporting its next-generation immunotherapy program, Bria-OTS+, and additional details will be available on March 17, 2026.
03-10 11:30
